<p>RNS 編號：9091T Ondine Biomedical Inc.2026 年 2 月 20 日</p>
<p>TR-1：主要持股通知的標準表格</p>
<ol>
<li>發行人詳情</li>
</ol>
<p>ISIN</p>
<p>CA68234M2058</p>
<p>發行人名稱</p>
<p>ONDINE BIOMEDICAL INC</p>
<p>英國或非英國發行人</p>
<p>非英國</p>
<ol>
<li>通知原因</li>
</ol>
<p>其他</p>
<p>評論</p>
<p>根據章程的 1% 變動</p>
<ol>
<li>受通知義務的人的詳細信息</li>
</ol>
<p>姓名</p>
<p>M&amp;G Plc</p>
<p>註冊辦公室所在城市（如適用）</p>
<p>倫敦</p>
<p>註冊辦公室所在國家（如適用）</p>
<p>英國</p>
<ol>
<li>股東的詳細信息</li>
</ol>
<p>如果與上述受通知義務的個人不同，股東的全名</p>
<p>註冊辦公室所在城市（如適用）</p>
<p>註冊辦公室所在國家（如適用）</p>
<ol>
<li>超過或達到閾值的日期</li>
</ol>
<p>2026 年 2 月 11 日</p>
<ol>
<li>發行人通知的日期</li>
</ol>
<p>2026 年 2 月 12 日</p>
<ol>
<li>受通知義務的人的總持倉</li>
</ol>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>附加於股份的投票權百分比（8.A 總計）</td>
<td>通過金融工具的投票權百分比（8.B 1 + 8.B 2 總計）</td>
<td>兩者總和的百分比（8.A + 8.B）</td>
<td>發行人持有的投票權總數</td>
</tr>
<tr>
<td>超過或達到閾值時的結果情況</td>
<td>13.041900</td>
<td>0.000000</td>
<td>13.041900</td>
<td>67604901</td>
</tr>
<tr>
<td>先前通知的持倉（如適用）</td>
<td>12.974380</td>
<td>0.000000</td>
<td>12.974380</td>
<td></td>
</tr>
</tbody>
</table>
<ol>
<li>超過或達到閾值時的結果情況的通知詳情</li>
</ol>
<p>8A. 附加於股份的投票權</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>股份類別/類型 ISIN 代碼（如可能）</td>
<td>直接投票權數量（DTR5.1）</td>
<td>間接投票權數量（DTR5.2.1）</td>
<td>直接投票權的百分比（DTR5.1）</td>
<td>間接投票權的百分比（DTR5.2.1）</td>
</tr>
<tr>
<td>CA68234M2058</td>
<td></td>
<td>67604901</td>
<td></td>
<td>13.041900</td>
</tr>
<tr>
<td>小計 8.A</td>
<td>67604901</td>
<td>13.041900%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>8B1. 根據 (DTR5.3.1R.(1) (a)) 的金融工具</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>金融工具類型</td>
<td>小計 8.B1</td>
</tr>
<tr>
<td>到期日期</td>
<td></td>
</tr>
<tr>
<td>行使/轉換期限</td>
<td></td>
</tr>
<tr>
<td>如果行使/轉換該工具可獲得的投票權數量</td>
<td></td>
</tr>
<tr>
<td>投票權的百分比</td>
<td></td>
</tr>
</tbody>
</table>
<p>8B2. 根據 (DTR5.3.1R.(1) (b)) 具有類似經濟效果的金融工具</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>金融工具類型</td>
<td>小計 8.B2</td>
</tr>
<tr>
<td>到期日期</td>
<td></td>
</tr>
<tr>
<td>行使/轉換期限</td>
<td></td>
</tr>
<tr>
<td>實物或現金結算</td>
<td></td>
</tr>
<tr>
<td>投票權數量</td>
<td></td>
</tr>
<tr>
<td>投票權的百分比</td>
<td></td>
</tr>
</tbody>
</table>
<ol>
<li>關於受通知義務的人的信息</li>
</ol>
<ol>
<li>通過最終控制自然人或法律實體有效持有投票權和/或金融工具的控制企業的完整鏈條（如有必要請添加額外行）</li>
</ol>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>最終控制人</td>
<td>控制企業名稱</td>
<td>如果等於或高於可通知閾值的投票權百分比</td>
<td>如果等於或高於可通知閾值的金融工具投票權百分比</td>
<td>如果等於或高於可通知閾值的兩者總和</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Plc（母公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Group Regulated Entity Holding Company Limited（M&amp;G Plc 的全資子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Group Limited（M&amp;G Group Regulated Entity Holding Company Limited 的全資子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G FA Limited（M&amp;G Group Limited 的全資子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Investment Management Limited（M&amp;G FA Limited 的全資子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
</tbody>
</table>
<ol>
<li>在代理投票的情況下</li>
</ol>
<p>代理持有人姓名</p>
<p>持有的投票權數量和百分比</p>
<p>持有投票權的截止日期</p>
<ol>
<li>附加信息</li>
</ol>
<ol>
<li>完成日期</li>
</ol>
<p>2026 年 2 月 12 日</p>
<ol>
<li>完成地點</li>
</ol>
<p>倫敦，英國</p>
<p>此信息由 RNS 提供，RNS 是倫敦證券交易所的新聞服務。RNS 獲得金融行為監管局的批准，作為英國的主要信息提供者。有關使用和分發此信息的條款和條件可能適用。如需更多信息，請聯繫 rns@lseg.com 或訪問 www.rns.com。</p>
<p>RNS 可能會使用您的 IP 地址以確認遵守條款和條件，分析您與本通信中包含的信息的互動方式，並在我們的商業服務中以匿名方式與他人共享此分析。如需有關 RNS 和倫敦證券交易所如何使用您提供的個人數據的更多信息，請參見我們的隱私政策。結束 HOLPPUWWPUPQGMU</p>

OCEAW

OCEA

<p>M&G Plc 已通知其在 Ondine Biomedical Inc. 的持股變動，當前持股比例為 13.0419%，已超過 13% 的閾值。該變動於 2026 年 2 月 12 日報告，閾值在 2026 年 2 月 11 日達到。通知中包括 M&G Plc 及其子公司直接和間接持有的投票權的詳細信息</p>

<p>RNS Number : 9091T Ondine Biomedical Inc. 20 February 2026</p>
<div class="lb-trans"><p>RNS 編號：9091T Ondine Biomedical Inc.2026 年 2 月 20 日</p>
</div><p>TR-1: Standard form for notification of major holdings</p>
<div class="lb-trans"><p>TR-1：主要持股通知的標準表格</p>
</div><p>1. Issuer Details</p>
<div class="lb-trans"><ol>
<li>發行人詳情</li>
</ol>
</div><p>ISIN</p>
<div class="lb-trans"><p>ISIN</p>
</div><p>CA68234M2058</p>
<div class="lb-trans"><p>CA68234M2058</p>
</div><p>Issuer Name</p>
<div class="lb-trans"><p>發行人名稱</p>
</div><p>ONDINE BIOMEDICAL INC</p>
<div class="lb-trans"><p>ONDINE BIOMEDICAL INC</p>
</div><p>UK or Non-UK Issuer</p>
<div class="lb-trans"><p>英國或非英國發行人</p>
</div><p>Non-UK</p>
<div class="lb-trans"><p>非英國</p>
</div><p>2. Reason for Notification</p>
<div class="lb-trans"><ol>
<li>通知原因</li>
</ol>
</div><p>Other</p>
<div class="lb-trans"><p>其他</p>
</div><p>Comments</p>
<div class="lb-trans"><p>評論</p>
</div><p>Movement of 1% as per Articles</p>
<div class="lb-trans"><p>根據章程的 1% 變動</p>
</div><p>3. Details of person subject to the notification obligation</p>
<div class="lb-trans"><ol>
<li>受通知義務的人的詳細信息</li>
</ol>
</div><p>Name</p>
<div class="lb-trans"><p>姓名</p>
</div><p>M&amp;G Plc</p>
<div class="lb-trans"><p>M&amp;G Plc</p>
</div><p>City of registered office (if applicable)</p>
<div class="lb-trans"><p>註冊辦公室所在城市（如適用）</p>
</div><p>London</p>
<div class="lb-trans"><p>倫敦</p>
</div><p>Country of registered office (if applicable)</p>
<div class="lb-trans"><p>註冊辦公室所在國家（如適用）</p>
</div><p>United Kingdom</p>
<div class="lb-trans"><p>英國</p>
</div><p>4. Details of the shareholder</p>
<div class="lb-trans"><ol>
<li>股東的詳細信息</li>
</ol>
</div><p>Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above</p>
<div class="lb-trans"><p>如果與上述受通知義務的個人不同，股東的全名</p>
</div><p>City of registered office (if applicable)</p>
<div class="lb-trans"><p>註冊辦公室所在城市（如適用）</p>
</div><p>Country of registered office (if applicable)</p>
<div class="lb-trans"><p>註冊辦公室所在國家（如適用）</p>
</div><p>5. Date on which the threshold was crossed or reached</p>
<div class="lb-trans"><ol>
<li>超過或達到閾值的日期</li>
</ol>
</div><p>11-Feb-2026</p>
<div class="lb-trans"><p>2026 年 2 月 11 日</p>
</div><p>6. Date on which Issuer notified</p>
<div class="lb-trans"><ol>
<li>發行人通知的日期</li>
</ol>
</div><p>12-Feb-2026</p>
<div class="lb-trans"><p>2026 年 2 月 12 日</p>
</div><p>7. Total positions of person(s) subject to the notification obligation</p>
<div class="lb-trans"><ol>
<li>受通知義務的人的總持倉</li>
</ol>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% of voting rights attached to shares (total of 8.A)</td>
<td>% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)</td>
<td>Total of both in % (8.A + 8.B)</td>
<td>Total number of voting rights held in issuer</td>
</tr>
<tr>
<td>Resulting situation on the date on which threshold was crossed or reached</td>
<td>13.041900</td>
<td>0.000000</td>
<td>13.041900</td>
<td>67604901</td>
</tr>
<tr>
<td>Position of previous notification (if applicable)</td>
<td>12.974380</td>
<td>0.000000</td>
<td>12.974380</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>附加於股份的投票權百分比（8.A 總計）</td>
<td>通過金融工具的投票權百分比（8.B 1 + 8.B 2 總計）</td>
<td>兩者總和的百分比（8.A + 8.B）</td>
<td>發行人持有的投票權總數</td>
</tr>
<tr>
<td>超過或達到閾值時的結果情況</td>
<td>13.041900</td>
<td>0.000000</td>
<td>13.041900</td>
<td>67604901</td>
</tr>
<tr>
<td>先前通知的持倉（如適用）</td>
<td>12.974380</td>
<td>0.000000</td>
<td>12.974380</td>
<td></td>
</tr>
</tbody>
</table>
</div><p>8. Notified details of the resulting situation on the date on which the threshold was crossed or reached</p>
<div class="lb-trans"><ol>
<li>超過或達到閾值時的結果情況的通知詳情</li>
</ol>
</div><p>8A. Voting rights attached to shares</p>
<div class="lb-trans"><p>8A. 附加於股份的投票權</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class/Type of shares ISIN code(if possible)</td>
<td>Number of direct voting rights (DTR5.1)</td>
<td>Number of indirect voting rights (DTR5.2.1)</td>
<td>% of direct voting rights (DTR5.1)</td>
<td>% of indirect voting rights (DTR5.2.1)</td>
</tr>
<tr>
<td>CA68234M2058</td>
<td></td>
<td>67604901</td>
<td></td>
<td>13.041900</td>
</tr>
<tr>
<td>Sub Total 8.A</td>
<td>67604901</td>
<td>13.041900%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>股份類別/類型 ISIN 代碼（如可能）</td>
<td>直接投票權數量（DTR5.1）</td>
<td>間接投票權數量（DTR5.2.1）</td>
<td>直接投票權的百分比（DTR5.1）</td>
<td>間接投票權的百分比（DTR5.2.1）</td>
</tr>
<tr>
<td>CA68234M2058</td>
<td></td>
<td>67604901</td>
<td></td>
<td>13.041900</td>
</tr>
<tr>
<td>小計 8.A</td>
<td>67604901</td>
<td>13.041900%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p>8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))</p>
<div class="lb-trans"><p>8B1. 根據 (DTR5.3.1R.(1) (a)) 的金融工具</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of financial instrument</td>
<td>Sub Total 8.B1</td>
</tr>
<tr>
<td>Expiration date</td>
<td></td>
</tr>
<tr>
<td>Exercise/conversion period</td>
<td></td>
</tr>
<tr>
<td>Number of voting rights that may be acquired if the instrument is exercised/converted</td>
<td></td>
</tr>
<tr>
<td>% of voting rights</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>金融工具類型</td>
<td>小計 8.B1</td>
</tr>
<tr>
<td>到期日期</td>
<td></td>
</tr>
<tr>
<td>行使/轉換期限</td>
<td></td>
</tr>
<tr>
<td>如果行使/轉換該工具可獲得的投票權數量</td>
<td></td>
</tr>
<tr>
<td>投票權的百分比</td>
<td></td>
</tr>
</tbody>
</table>
</div><p>8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))</p>
<div class="lb-trans"><p>8B2. 根據 (DTR5.3.1R.(1) (b)) 具有類似經濟效果的金融工具</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of financial instrument</td>
<td>Sub Total 8.B2</td>
</tr>
<tr>
<td>Expiration date</td>
<td></td>
</tr>
<tr>
<td>Exercise/conversion period</td>
<td></td>
</tr>
<tr>
<td>Physical or cash settlement</td>
<td></td>
</tr>
<tr>
<td>Number of voting rights</td>
<td></td>
</tr>
<tr>
<td>% of voting rights</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>金融工具類型</td>
<td>小計 8.B2</td>
</tr>
<tr>
<td>到期日期</td>
<td></td>
</tr>
<tr>
<td>行使/轉換期限</td>
<td></td>
</tr>
<tr>
<td>實物或現金結算</td>
<td></td>
</tr>
<tr>
<td>投票權數量</td>
<td></td>
</tr>
<tr>
<td>投票權的百分比</td>
<td></td>
</tr>
</tbody>
</table>
</div><p>9. Information in relation to the person subject to the notification obligation</p>
<div class="lb-trans"><ol>
<li>關於受通知義務的人的信息</li>
</ol>
</div><p>2. Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entities (please add additional rows as necessary)</p>
<div class="lb-trans"><ol>
<li>通過最終控制自然人或法律實體有效持有投票權和/或金融工具的控制企業的完整鏈條（如有必要請添加額外行）</li>
</ol>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ultimate controlling person</td>
<td>Name of controlled undertaking</td>
<td>% of voting rights if it equals or is higher than the notifiable threshold</td>
<td>% of voting rights through financial instruments if it equals or is higher than the notifiable threshold</td>
<td>Total of both if it equals or is higher than the notifiable threshold</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Plc (Parent company)</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Group Regulated Entity Holding Company Limited (wholly owned subsidiary of M&amp;G Plc)</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Group Limited (wholly owned subsidiary of M&amp;G Group Regulated Entity Holding Company Limited)</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G FA Limited (wholly owned subsidiary of M&amp;G Group Limited)</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Investment Management Limited (wholly owned subsidiary of M&amp;G FA Limited)</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>最終控制人</td>
<td>控制企業名稱</td>
<td>如果等於或高於可通知閾值的投票權百分比</td>
<td>如果等於或高於可通知閾值的金融工具投票權百分比</td>
<td>如果等於或高於可通知閾值的兩者總和</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Plc（母公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Group Regulated Entity Holding Company Limited（M&amp;G Plc 的全資子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Group Limited（M&amp;G Group Regulated Entity Holding Company Limited 的全資子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G FA Limited（M&amp;G Group Limited 的全資子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
<tr>
<td>M&amp;G Plc</td>
<td>M&amp;G Investment Management Limited（M&amp;G FA Limited 的全資子公司）</td>
<td>13.041900%</td>
<td></td>
<td>13.041900%</td>
</tr>
</tbody>
</table>
</div><p>10. In case of proxy voting</p>
<div class="lb-trans"><ol>
<li>在代理投票的情況下</li>
</ol>
</div><p>Name of the proxy holder</p>
<div class="lb-trans"><p>代理持有人姓名</p>
</div><p>The number and % of voting rights held</p>
<div class="lb-trans"><p>持有的投票權數量和百分比</p>
</div><p>The date until which the voting rights will be held</p>
<div class="lb-trans"><p>持有投票權的截止日期</p>
</div><p>11. Additional Information</p>
<div class="lb-trans"><ol>
<li>附加信息</li>
</ol>
</div><p>12. Date of Completion</p>
<div class="lb-trans"><ol>
<li>完成日期</li>
</ol>
</div><p>12-Feb-2026</p>
<div class="lb-trans"><p>2026 年 2 月 12 日</p>
</div><p>13. Place Of Completion</p>
<div class="lb-trans"><ol>
<li>完成地點</li>
</ol>
</div><p>London, United Kingdom</p>
<div class="lb-trans"><p>倫敦，英國</p>
</div><p>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</p>
<div class="lb-trans"><p>此信息由 RNS 提供，RNS 是倫敦證券交易所的新聞服務。RNS 獲得金融行為監管局的批准，作為英國的主要信息提供者。有關使用和分發此信息的條款和條件可能適用。如需更多信息，請聯繫 rns@lseg.com 或訪問 www.rns.com。</p>
</div><p>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END HOLPPUWWPUPQGMU</p>
<div class="lb-trans"><p>RNS 可能會使用您的 IP 地址以確認遵守條款和條件，分析您與本通信中包含的信息的互動方式，並在我們的商業服務中以匿名方式與他人共享此分析。如需有關 RNS 和倫敦證券交易所如何使用您提供的個人數據的更多信息，請參見我們的隱私政策。結束 HOLPPUWWPUPQGMU</p>
</div>

REG - Ondine Biomedical M&G PLC - 公司持股情況